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Edited by Jesus AvilaAbstract Previously, we reported that decreased brain-speciﬁc
angiogenesis inhibitor 2 (BAI2) induced increased VEGF expres-
sion. The regulatory mechanisms for this process are not under-
stood. Here we show that GA-binding protein gamma (GABPc)
associates with the cytoplasmic domain of BAI2, and GABPa/c
or GABPa/b works as a transcriptional repressor of VEGF in
SHSY5Y cells. Transcriptional activity of wild-type VEGF pro-
moter was signiﬁcantly increased in anti-sense BAI2-transfected
cells, but not that of VEGF promoter harboring mutated GABP
sites. In in vivo focal cerebral ischemia model, the decrease in
BAI2 accompanied by decreased GABPa and GABPc elicited
increased VEGF expression before the onset of HIF-1a. Our re-
sults point out that BAI2 controls VEGF transcription through
GABP under normal conditions and cerebral ischemia.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Angiogenesis, a process by which new blood vessels are
formed from preexisting ones, plays an important role in a
wide range of physiological and pathological processes includ-
ing wound healing and tumor growth, and is controlled by the
balance between angiogenic factors and inhibitors. When
angiogenic factors such as vascular endothelial growth factor
(VEGF) or basic ﬁbroblast growth factor prevail over angio-
genesis inhibitors, angiogenesis occurs [1].
GA-binding protein (GABP) is an ETS transcription factor
that controls gene expression in cell cycle control, protein syn-
thesis, and cellular metabolism [2]. GABP is unique among ETSAbbreviations: VEGF, vascular endothelial growth factor; BAI2,
brain-speciﬁc angiogenesis inhibitor 2; GABP, GA-binding protein;
CV-1 cells, Green monkey kidney epithelial cells; SDS–PAGE, sodium
dodecyl sulfate–polyacrylamide gel electrophoresis; IP, immunopre-
cipitation; EMSA, electrophoretic mobility shift assay; ChIP, chro-
matin immunoprecipitation; MCA, middle cerebral artery; TTC,
triphenyl tetrazolium chloride
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doi:10.1016/j.febslet.2005.12.086factors, since the active complex is an obligate heterotetramer
that is composed of two distinct proteins. GABPa includes
the ETS DNA binding domain, while two alternate subunits,
GABPb or GABPc, contain ankyrin repeats and the transcrip-
tional activation domain. The DNA-binding subunit GABPa
cannot aﬀect transcription by itself, but can modify GABP-
dependent transcription in the presence of its associated sub-
units, GABPb and GABPc, which regulate GABP-mediated
transcription by competing with each other [3,4].
Previously, we isolated and characterized the murine homo-
logue brain-speciﬁc angiogenesis inhibitor 2 (mBAI2) of human
BAI2, which is involved in the early stages of neovasculariza-
tion of cerebral cortex after ischemia and the predicted structure
of the mBAI2 protein suggests that mBAI2 may be a G-protein
coupled receptor in the brain [5,6]. To date, however, there are
no known ligands to bind and modulate BAI2. The increased
VEGF expressions observed in anti-sense BAI2 cDNA transfec-
ted cells and during focal ischemia following the decreased
BAI2 suggest a potential negative inﬂuence of angiostatic
BAI2 on the angiogenic VEGF [5]. Thus, we hypothesized that
cerebral ischemia could trigger hypoxia-adaptive molecular
responses in neurons by suppression of brain-speciﬁc angio-
static genes, such as BAI2, and thereby eventually lead to stim-
ulation of angiogenic proteins, such as VEGF.
In this study, we investigated the potential link underlying
the inverse correlation between BAI2 and VEGF. A yeast-
based two-hybrid assay was used to screen for BAI2-interacting
cytoplasmic proteins in a human adult brain cDNA library,
and GABPc was identiﬁed as a binding protein to the cytoplas-
mic domain of BAI2. We found that GABP subunit, GABPa/b
or GABPa/c, acts as a transcriptional repressor in the regula-
tion of VEGF expression at the promoter level. The decreased
BAI2 during cerebral ischemia causes suppression of the avail-
able GABP subunit, thereby leading to increased VEGF in con-
cert with HIF-1a, a transcriptional enhancer. Our study
indicates that the regulation of the GABP by BAI2 is a novel
mechanism involved in the control of VEGF expression for
ischemia-induced neovascularization of brain as well as under
normal conditions.2. Materials and methods
2.1. Yeast two-hybrid assay
A yeast two-hybrid screening system was used to isolate cDNAs
encoding proteins that interact with the cytoplasmic region of BAI2.
To generate pLexA fusion constructs (pLexA202-mBAI2 S1/AS1,blished by Elsevier B.V. All rights reserved.
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sponding to each partial cytoplasmic region of mBAI2 was subcloned
into pLexA202, and was used to screen a fetal brain cDNA library.
The PCR primers: S1, 5 0-TCCTGTCTCGTGGGT-3 0; S2, 5 0-
TTCCAACCACC-ACCA-3 0; S3, 5 0-ACGGTAGCCCACACT-30;
S4, 5 0-ACTT-TGAGCCTGCAG-3 0; S5, 5 0-AACCCTGTGTA-
CATG-3 0; AS1, 5 0-AGCCCAGTGTCATAG-3 0; AS2, 5 0-GGTCATT-
CCATACG-G-3 0. The yeast reporter strain EGY48 (p80p-lacz; MAT,
his, trp1, ura3, LexAop(x6)-LEU2) was sequentially transformed with
pLexA-cytoBAI2 and the pB42-human adult brain cDNA library, and
cotransformants were screened as described [7]. Plasmid DNA from
positive clones was isolated and sequenced.
2.2. Quantitative b-galactosidase assay
For relative quantiﬁcation of protein–protein interactions, b-galac-
tosidase assays were performed. pLexA-BD-BAI2 was made by sub-
cloning a partial cytoplasmic region of BAI2 (4247–4572 bp) into
pLexA202. Full-length or three speciﬁc regions of the GABPc were
fused to pB42-AD. Yeast strains co-transformed by pLexA- and
pB42-constructs were grown in supplemented minimal galactose med-
ium lacking uracil, tryptophan and histidine at 30 C for 24 h. They
were then analyzed as described [8]. The activity of b-galactosidase
was calculated in Miller units with the formula units = A420 · 1000/
A600 · volume · reaction time. Each sample was performed in tripli-
cate.
2.3. Cell culture and transfection
SHSY5Y neuroblastoma and Green monkey kidney epithelial (CV-
1) cells or human conjunctival (clone 1-5c-4) cells were cultured in
DMEM or RPMI1640 containing 10% fetal bovine serum and antibi-
otic/antimycotic solution. Cells were then transfected with pFLAG-
tagged GABPc, control pFLAG vector or pREP4-anti-BAI2 plasmid
[5] using FuGENE 6 (Roche) following the manufacturer’s protocol.
Colonies surviving in the G418- or hygromycin-containing medium
were isolated and analyzed.
2.4. Production of anti-GABPc antibody and Western blot analysis
GST-GABPc fusion protein was prepared by subcloning of C-termi-
nal portion containing the GABPc-speciﬁc region (279–360 amino acid
residues) into the pGEX-4T as previously described [7], and rabbit
antiserum recognizing GABPc was prepared using this protein. The
serum recognizing GABPc was ﬁltered through a column of GST-
GABPc fusion protein, and the column was eluted with a low-pH buf-
fer. It was then ﬁltered through a column of GST protein to remove
the anti-GST antibody component. Cell lysates were prepared from
rat cerebral cortex tissues, resolved by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE), transferred, and blotted
with anti-BAI2 serum [5], anti-GABPc serum, anti-GABPa, anti-
GABPb (Santa Cruz), anti-VEGF (NeoMarkers), or anti-HIF-1a (a
gift form Dr. J.W. Park), and anti-rabbit, anti-goat, or anti-mouse
Ig-HRP (Amersham) as described [5].2.5. GST pull-down and immunoprecipitation (IP) assay
Escherichia coli BL21 cells transformed with each of pGEX-4T-
BAI2-cytoplasm fusions were grown at 37 C, and synthesis was
induced by addition of 0.2 mM isopropyl-b-D-galactopyranoside as a
ﬁnal concentration. The GST-fusion proteins were isolated with gluta-
thione-Sepharose-4B beads (Pharmacia Biotech), washed and incu-
bated with [35S] methionine-labeled GABPc produced by in vitro
translation using the TNT-coupled transcription–translation system
(Promega). Bound proteins were eluted, analyzed by SDS–PAGE
and autoradiographed.
IP was performed as previously described [7]. Brieﬂy, SHSY5Y cells
were resuspended in RIPA buﬀer, and solubilized supernatant was
incubated with protein A/G beads and preimmune or anti-BAI2 serum
for 2 h. Immunoprecipitates were resolved by SDS–PAGE, transferred
and blotted with anti-GABPc or anti-GABPa (Santa Cruz) and anti-
rabbit or anti-goat Ig-HRP (Amersham).
2.6. VEGF promoter-reporter assay
A 2951-bp fragment containing the 5 0 ﬂanking region and transcrip-
tional start site of the VEGF gene (2362  +589 bp) was prepared by
genomic PCR [9], and cloned into the pGL3-Basic vector (Promega) tomake the VEGF-Luc promoter construct. Also, GABP binding site-
directed mutagenesis of the VEGF-Luc promoter construct was
performed as follows. GABP m1 and GABP m2 were generated by
replacing the GABP binding element TTCCCT in 952/947 and
CGGATG in 236/231 with GAATTC and CTCGAG, respectively.
GABP m1 and m2 was prepared by replacing both sites.
CV-1 cells or stably anti-BAI2 transfected SHSY5Y cells were
transfected with the indicated amount of expression plasmids
(pGL3-VEGF-Luc with pcDNA3-GABPa, b, c) and the pCMVb as
an internal control by using FuGENE 6. Total amounts of DNAs were
kept constant by adding appropriate amounts of pcDNA3. At 48 h
after transfection, cells were washed, harvested and assayed with the
Dual Luciferase Reporter Assay System (Promega) as described [10].
The transfection experiments were performed at least three times. Data
are presented as means ± S.E.M. of 3–4 independent experiments with
triplicate dishes. The relative fold induction in each luciferase activity
was determined by calculating the GABP/vector ratio when the vector
(VEGF-Luc) activity was set at 1.
2.7. Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was performed with the
following DNA probes and their complementary strands. The syn-
thetic oligonucleotides were labeled and incubated for 30 min at room
temperature with 10 lg of nuclear extract from CV-1 cells in a 20 ll
reaction containing 10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA,
1 mM b-mercaptoethanol, 1% Ficoll and 2.0 lg poly (dI–dC). For
supershift experiments, reactions were preincubated for 20 min on ice
with anti-GABPa or preimmune serum. Products were analyzed by
SDS–PAGE, dried and autoradiographed.
2.8. Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed on SHSY5Y
and human conjunctival cells with ChIP assay kit (Upstate) largely fol-
lowing the supplier’s recommendations. Cells grown on 100-mm dishes
were collected and cross linked using 1% formalin for 10 min at room
temperature, and the extracts were sonicated until the DNA fragments
were 500–800 bp in size. Cell extracts were subsequently incubated with
no antibody, 2 lg IgG or antibody against GABP alpha overnight at
4 C. The extracts were incubated with salmon sperm DNA/protein
A-sepharose beads (Upstate) for 1 h. After extensive washing of the
beads, proteins were eluted and reversed by heating for 4 h at 65 C.
After DNA puriﬁcation, PCR was performed at 35–40 cycles. Primers
were: GABP site 1 (211 bp); 5 0-TCCCCCTTTGGGTTTTGCCAGA-
3 0 (sense), 5 0-TCAAAGTGAGCGGCAGCCAA-30 (antisense), GABP
site 2 (200 bp); 5 0-AGAGGGAACGGCTCTCAGGC-3 0 (sense), 5 0-
CTCTGCGGACGCCCAGTGAA-3 0 (antisense).
2.9. RT-PCR
Total RNAs were prepared from cultured cells and reverse transcrip-
tion was performed as described [5,7]. The annealing temperature was
58 C for GABPa, GABPb and GABPc, and 60 C for BAI2, VEGF,
HIF-1a, b-actin and GAPDH. The ampliﬁcation products were ana-
lyzed on agarose gels and visualized by ultraviolet epiﬂuorescence.
PCR primers: S1, 5 0-GTGTCCAGCCTTCCATGAGATG-3 0 and
AS1, 5 0-TTTCCGCATCCACCATGAAGC-3 0 for hBAI2; S1, 5 0-
GCAGACCAAAG-AAAGATAGAGCAAG-3 0 and AS1, 5 0-CGCC-
TCGGCTTGTCACAT-30 for hVEGF; S1, 5 0-AACATGATGGTT-
CACTTTTTCAAGC-3 0 and AS1, 5 0-GTCAGCTGTGG-TAATCC-
ACTTTCAT-30 for hHIF-1a; S1, 5 0-ACTACAGTGTTCTTTGG-
ATGCTCATG-3 0 and AS1, 5 0-TGTGGACCACTGTATGGGATC-
ATAGG-3 0 for hGABPa; S1, 5 0-GAATTCAGCTTGGAAATTTGC-
ACT-3 0 and AS1, 5 0-TTAAACAGCTTCTTT-ATTAGTCT-3 0 for
hGABPb; S1, 5 0-CATCCAAGGC-AACAGATGAAACGG-3 0 and
AS1, 5 0-TTGGATGACTGCGGCAAAGCACAC-3 0 for hGABPc,
respectively.
2.10. Focal ischemia model in rat
Sprague-Dawley rats (200 g) were anesthetized with 4% halothane in
an anesthetic chamber and maintained with 1% halothane in 100% O2
using a rodent mask. Operation for focal ischemia was performed as
described [5]. The rat was sacriﬁced after the time course of ischemia
(0, 1, 2, 4, 8, 24 h) without reperfusion. The brain slices were stained
with 2% triphenyl tetrazolium chloride (TTC) to visualize and measure
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the occlusion of middle cerebral artery (MCA) and the corresponding
portion of sham-operated cerebral cortex were selected for production
of protein.
2.11. Statistics
Experimental diﬀerences were tested for statistical signiﬁcance using
ANOVA and Students’ t-test. A P value of less than 0.05 was consid-
ered signiﬁcant.3. Results and discussion
3.1. Interaction of GABPc with the cytoplasmic region of
mBAI2
The yeast two-hybrid system was used to identify proteins
that associate with the cytoplasmic region of mBAI2. Initially,
we found that the C-terminal residues (3830–4572 bp) of
mBAI2 had auto-transcriptional activity. Six mBAI2 cytoplas-
mic protein fragments were examined to ﬁnd the source of the
auto-transcriptional activity (Fig. 1A) and nucleotide residues
4247–4572 of mBAI2 showed the least b-gal activity and were
used as bait (Fig. 1B). From 6 · 105 transformants, several po-
sitive clone were isolated, one of which was hGABPc.
Next, we examined the binding of mBAI2 to GABPc in cul-
tured cells. The in vitro translated GABPc protein (38 kDa)
was found to interact with GST–BAI2 fusion proteins by pull-Fig. 1. Direct interaction of GABPc with the cytoplasm region of BAI2. (A)
in yeast two-hybrid system. Full-length or deletion variants of the BAI2
nucleotide residues. (B) To examine autotranscriptional activity, full-length o
with pB42-AD empty vector, and b-galactosidase activities were measured. (
incubated with equivalent amounts of the 35S-labeled GABPc produced by in
percent of the labeled proteins used in binding reaction were loaded as inpu
GST–BAI2. (D) SHSY5Y cells were transfected with pFLAG-GABPc or th
Each cell lysate in (D) was immunoprecipitated with anti-BAI2 serum, and bl
blot in (E) was reprobed with anti-GABPa antibody. An arrow indicates thdown assay (Fig. 1C). For IP analysis, we obtained stably
GABPc-overexpressing SHSY5Y neuroblastoma cells, which
express endogenous BAI2 (Fig. 1D). After immunoprecipitat-
ing this cell lysate with anti-BAI2 serum, proteins were blotted
with anti-GABPc antibody and GABPc was detected, indicat-
ing that GABPc interacted with the cytoplasmic region of
BAI2 (Fig. 1E). Interestingly, GABPa, which makes a hetero-
dimeric complex with GABPc, was found when the same blot
was reprobed with goat anti-GABPa antibody (Fig. 1F). It
indicated that GABPa also bound to the cytoplasmic region
of BAI2 through interaction with GABPc.
3.2. Full-length of GABPc has high aﬃnity to BAI2
To determine which part of GABPc is essential for interac-
tion with the BAI2, full-length and three speciﬁc regions of
GABPc (N-terminal portion containing ankyrin repeats, mid-
dle portion common to GABPc and GABPb, and C-terminal
portion containing the GABPc-speciﬁc region) were fused to
pB42-AD (Fig. 2A). Co-transformation with pLexA-BD-
BAI2 demonstrated that the whole region of GABPc was nec-
essary for strong interaction with the cytoplasmic region of
BAI2 (Fig. 2B).
3.3. Expression of VEGF in GABPc-transfected SHSY5Y cells
Our previous study demonstrated increased VEGF expres-
sion in SHSY5Y cells transfected with anti-sense BAI2 [5].Schematic representation of cytoplasmic fragment of BAI2 used as bait
cytoplasmic region are shown as lines. Numbers in parentheses are
r deletion variants of the BAI2 cytoplasmic region were cotransformed
C) GST–BAI2 fusion protein bound to glutathione-agarose beads was
vitro translation, resolved by SDS–PAGE, and autoradiographed. Ten
t. An arrow indicates GABPc protein (38 kDa) that interacted with
e control vector, and immunoblotted with anti-GABPc antibody. (E)
otted with anti-GABPc antibody. An arrow indicates GABPc. (F) The
e 52 kDa GABPa, which overlapped in size with rabbit IgG.
Fig. 2. Characteristic binding of GABPc with BAI2 and eﬀects of
overexpressed GABPc. (A) Speciﬁc regions of the GABPc are shown.
(B) The regions of GABPc required for the interaction with cytoplas-
mic domain of BAI2 were determined by assessing b-galactosidase
activity. Numbers in parentheses are the number of amino acids. (C)
RT-PCR analysis of BAI2 and VEGF mRNA in SHSY5Y cells stably
transfected with GABPc. Expression of b-actin conﬁrms the relative
amounts and ﬁdelity of the RNA. M, molecular size marker.
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analyses were performed in SHSY5Y cells, which were stably
transfected with a GABPc construct (Fig. 2C). In GABPc-
overexpressed cells, GABPc expression increased, whereas
BAI2 did not change. However, VEGF expression decreased,
indicating that GABPc might suppress the VEGF expression.
Expression of GABPa was unchanged, whereas GABPb de-
creased slightly (Fig. 2C).
3.4. Suppression of VEGF expression by GABP and binding of
GABPa to VEGF promoter
Because overexpressed GABPc, which makes a heterodimer
with GABPa, suppressed VEGF expression (Fig. 2C), CV-1
cells were transiently co-transfected with VEGF-luciferase
construct and increasing doses of GABP subunits, either GAB-
Pa/b or GABPa/c, which enable GABPa to enter the nucleus
and stimulate target gene transcription [3,4]. Transfection of
GABP subunits signiﬁcantly decreased the transcriptional
activity of VEGF (Fig. 3A).To elucidate whether the GABPa transcription factor actu-
ally binds to VEGF promoter, gel mobility-shift assays were
performed. Inspection of VEGF 5 0-ﬂanking sequences by bioin-
formatics analysis revealed two potential GABP binding sites.
Potential GABP binding site 1 (960/941, AGGTCCTC-
TTCCCTCCCAGT) was in the reverse orientation, whereas
potential GABP binding site 2 (243/224, CCGGGGG-
CGGATGGGTAATT) was in the same orientation as the
transcriptional unit. Two double-stranded DNA probes that
corresponded to these two sites were used in EMSA with
CV-1 cell nuclear extracts, which express high levels of GABPa.
Two species fromCV-1 cells were found to bind with the GABP
binding site 1 (Fig. 3B, left column) and 2 (Fig. 3B, right col-
umn). Similar two complexes were reported to be formed
between VEGF promoter and GABPa monomer/dimer [11].
Thus, the upper/lower bands corresponded to the dimeric/
monomeric complex, respectively. In addition, two bands were
abrogated by an anti-GABPa antiserum, indicating that GABP
subunits participated as transcription factors in the regulation
of VEGF expression at the promoter level. In addition, bind-
ings of endogenous GABPa to the each GABP binding site
(sites 1 and 2) on the VEGF promoter sequences were con-
ﬁrmed by chromatin immunoprecipitation (Fig. 3C).
To observe whether the mutation of putative GABP binding
sites in the VEGF promoter sequence results in a loss of tran-
scriptional repression in response to GABP subunits, CV-1
cells were transiently cotransfected with wild-type VEGF-
Luc promoter construct or mutated VEGF-Luc promoter con-
struct that has changed GABP binding site and increasing
amounts of either GABPa/b or GABPa/c expression plasmids.
Transfection of GABPa/c or GABPa/b, signiﬁcantly decreased
the transcriptional activity of wild-type, GABP m1 or GABP
m2 VEGF promoter, but not that of GABP m1 and m2 VEGF
promoter (Fig. 3D), indicating that GABPa acts as a transcrip-
tional repressor of VEGF expression.
3.5. Increased VEGF expression in anti-sense GABPa- or
anti-sense GABPc-transfected SHSY5Y cells
To test that decreased GABP binding on the VEGF pro-
moter sequence results in activated VEGF promoter activity
and thereby increased VEGF expression, RT-PCR analysis of
VEGF was performed in SHSY5Y cells stably transfected with
anti-sense GABPa or GABPc construct. The expression of
GABPa or GABPc decreased, whereas VEGF increased in
anti-sense GABPa or GABPc transfected SHSY5Y cells com-
pared with vector transfected cells, though the magnitude of
increment was larger in anti-sense GABPa transfected cells
(Fig. 4A). However, expression of BAI2, GABPb or HIF-1a
did not change by decreased GABP binding on the VEGF pro-
moter (Fig. 4A). It conﬁrms that GABPa/c acts as repressive
transcriptional regulator on VEGF promoter activity.
3.6. Loss of BAI2 function leads to increased transcriptional
activity of VEGF promoter in SHSY5Y Cells
To observe the causal link between decreased BAI2 expres-
sion and increased VEGF promoter activity, stably anti-sense
BAI2 transfected SHSY5Y cells were transiently cotransfected
with wild-type VEGF-Luc promoter or GABP binding site-
mutated VEGF-Luc promoter. In the stably anti-sense BAI2-
transfected SHSY5Y cells, expression of endogenous VEGF
increased (Fig. 4B) as reported [5]. After cotransfection, the
transcriptional activity of wild-type VEGF promoter was
Fig. 3. GABP subunits act as transcriptional repressor for VEGF expression. (A) CV-1 cells were transiently cotransfected with VEGF-Luc
promoter and increasing doses of either GABPa/b or GABPa/c with CMV-b-gal as an internal control. After 48 h, luciferase activity was measured.
All values are means ± S.E.M. (n = 3). Asterisks indicate signiﬁcant diﬀerences between vector and GABP subunits group (\P < 0.05, \\P < 0.01). (B)
EMSA was performed with 32P-labeled double-stranded oligonucleotide probe for the GABP binding site 1 (lanes 1–4) or the site 2 (lanes 5–8) of
VEGF promoter using nuclear extract of CV-1 cells. Two complexes, upper (arrow head) and lower (arrow) bands, were formed with GABP binding
sites 1 and 2. (C) ChIP assays showed that GABPa binds to the GABP binding sites on human VEGF promoter sequences in the SHSY5Y and
human conjunctival cells. GABP site 1 or 2 represents promoter region containing of 5 0 (950)- or 3 0 (230)-GABP binding site on promoter
sequence (upper column). (D) CV-1 cells were transiently cotransfected with wild-type VEGF-Luc promoter or mutated VEGF-Luc promoters
having changed GABP binding site (GABP m1: TTCCCT in 952/947 was replaced; GABP m2: CGGATG in 236/231 was replaced; GABP m1
and m2: both sites were replaced) and increasing doses of either GABPa/b or GABPa/c with CMV-b-gal. All values are means ± S.E.M. (n = 4).
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VEGF promoter (Fig. 4C) in the BAI2-suppressed SHSY5Y
cells than that of in the control SHSY5Y cells. It indicates that
angiostatic BAI2 suppresses the VEGF promoter activity
through GABP transcription factors in cultured neuronal cells
under normal condition.3.7. Changes of BAI2 and GABP resulted in increased VEGF in
focal cerebral ischemia model in rat
Because there are no known ligands to bind with BAI2 and
modulate BAI2 activity, we examined the changes of GABPs
and VEGF in an in vivo rat focal cerebral ischemia model,
in which we observed the decreased BAI2 expression following
Fig. 4. Loss of GABPa/c or BAI2 function leads to increased transcription of the endogenous VEGF gene or the exogenous wild-type VEGF
promoter but not in the GABP site-mutated one. (A) RT-PCR analyses of VEGF, BAI2 and HIF-1a were performed in SHSY5Y cells stably
transfected with anti-sense GABPa (#1, #2) or GABPc (#3, #4) construct. Expression of GAPDH conﬁrms the relative amounts and ﬁdelity of the
RNA. (B) The endogenous VEGF expression was increased in the stably anti-sense BAI2-transfected SHSY5Y cells. (C) The transcriptional activity
of wild-type VEGF promoter (Wild) or mutant VEGF promoter (Mut, GABP m1 and m2) was measured in anti-sense BAI2-transfected SHSY5Y
cells. The results are means ± S.E.M. (n = 3). Asterisks indicate signiﬁcant diﬀerences in relative luciferase activity between groups.
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ischemic region of whole brain by TTC staining at 8 and 24 h
of the right MCA occlusion (Fig. 5A). The ischemic area in-
creased with time-dependent manner in the right ipsilateral
hemisphere.
Western blot analyses were done to observe the changes of
BAI2, GABPs, VEGF and HIF-1a expressions in ischemic
cerebral tissues. BAI2 decreased in the ischemic area after 1 h
compared with in the control cerebral cortex and the decreased
level was maintained until 4 h, but recovered at 8 h (Fig. 5B).
BAI2 level was signiﬁcantly decreased throughout all experi-
mental periods compared with that of control (Fig. 5C). GAB-
Pa initially dropped at 1 h, but recovered at 2 h. But, after 4 h,
it decreased again until 24 h. GABPc showed the same expres-
sion pattern throughout the time window of ischemia as GAB-
Pa. However, GABPb increased in the ischemic tissues
throughout the time window. VEGF increased in the ischemic
cortex after 1 h, peaked at 8 h, and it returned to basal level at
24 h after ischemia (Fig. 5B). Actually, there seems to recoverto basal level in GABPa and GABPc but a little decreased level
of VEGF at 2 h compared with that of 1 or 4 h (Fig. 5C). HIF-
1a was induced from 2 h and peaked at 8 h, but recovered to
control level at 24 h (Fig. 5B). Taken together, suppression of
the available GABP transcription factors led to the slightly in-
creased VEGF expression in the early phase of cerebral ische-
mia (around 1 h) before the onset of HIF-1a. However, in the
late phase (around 8 h), nearly dropped GABPa seemed to
work together with increased HIF-1a to create a peak in VEGF
expression. Therefore, our results showed that both decreased
GABP repressors and increased HIF-1a enhancer aﬀect VEGF
transcription in focal ischemia-induced angiogenesis of cerebral
tissues, and that a functional signiﬁcance of GABP repressors
as an additional factor in the regulation of angiogenesis after
cerebral ischemia.
Both GABPb and GABPc contain a nuclear localization sig-
nal (NLS) and are localized predominantly in the nucleus
regardless of the presence of GABPa. GABPa lacks an NLS
and its entry into the nucleus absolutely requires the concom-
Fig. 6. A schematic diagram showing the transcriptional regulation of
VEGF expression. It indicates that BAI2/GABP and HIF-1a act as
transcriptional repressors and enhancer of VEGF, respectively.
Fig. 5. Analyses of BAI2, GABP and VEGF in the in vivo focal
ischemic cerebral tissues. (A) The representative staining of infarct area
in focal ischemic rat cerebral tissues. MCA was occluded in given times
(8 and 24 h) and the brain slices were stained with 2% TTC to visualize
the infarct (white color) and non-infarct area (red color). (B) Western
blot analyses were performed for time sequencial expressions of BAI2,
GABPs, VEGF and HIF-1a in the focal ischemic rat cerebral tissues. C
is sham-operated cerebral cortex. The same blot was reprobed with
anti-actin antibody to control for loading. The data show one of three
representative experiments. (C) Densitometric analyses of Western blot
for BAI2, GABP and VEGF, which levels were normalized with
respect to the corresponding actin level. The values are means ±
S.E.M. (n = 3). Asterisks indicate signiﬁcant diﬀerences in relative
densitometric level (ratio of BAI2, GABP or VEGF versus actin value)
of each period compared with control (\\\P < 0.001).
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GABPc should bind GABPa in the cytoplasm to assist GAB-
Pa transport into the nucleus. Thus, GABPa acts as a tran-
scription factor only after forming a complex with its partner
protein GABPb or GABPc [3,4,12]. In this regard, our present
results suggest that suppression of the available GABP by the
deactivated BAI2 after ischemia leads to the depletion of the
available GABPa for nuclear GABPa2/b2 heterotetramer or
GABPa/c heterodimer formation (Fig. 6), both of which act
as transcriptional repressors for VEGF that contributes mainly
to the neovascularization after ischemia [13]. Collectively,
there exists a reciprocal relationship between BAI2 and VEGF
in the brain angiogenesis in which angiostatic BAI2 regulatesVEGF expression through GABPs after cerebral ischemia as
well as under normal conditions.
The hypoxia-induced upregulation of VEGF expression is
mediated both by activation of VEGF transcription through
HIF-1a and enhanced VEGF mRNA stability [14–16]. Also,
there are many very well characterized angiogenic and angio-
static factors that can modulate VEGF expression, in which
most of them are transcriptional activators [17]. In this study,
it seems that the contribution of BAI2–VEGF transcription
through GABP transcription factors after cerebral ischemia ap-
pears to bemarginal (Fig. 5C) compared to that of HIF-1a from
other studies [15,16]. However, our present study shows for the
ﬁrst time that GABP acts as a transcriptional repressor in the
regulation of VEGF expression and this ﬁnding is potentially
important for better understanding the regulation of VEGF,
one of the most speciﬁc and critical regulators of angiogenesis.
It was reported that GABP regulates gene expression
through its interaction with other transcription factors and
co-activators bound to the cognate motifs in the vicinity of
the GABP site, such as Sp1 [2,18]. The VEGF promoter was
found to contain two HIF-1 binding sites (975/968, 313/
306) [15] and one Sp1 binding site (240/232) in the vicin-
ity of the 5 0 (960/941) and 3 0 (243/224) GABP binding
sites (Fig. 6). It is supposed that GABP bound at the 3 0 binding
site and Sp1 may cooperate to regulate the VEGF promoter
[17]. Studies are undergoing to ﬁnd the mechanisms for the
regulation of VEGF promoter by cooperation of GABP with
these transcription factors.
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